<DOC>
	<DOCNO>NCT00043303</DOCNO>
	<brief_summary>The purpose research study test safety effectiveness Interferon gamma-1b ( IFN-g 1b ) inject subcutaneously ( skin ) treatment advance liver fibrosis cirrhosis patient chronic hepatitis C infection . IFN-g 1b currently approve treatment liver fibrosis .</brief_summary>
	<brief_title>Safety Efficacy Study Interferon Gamma-1b Hepatitis C Patients With Liver Fibrosis Cirrhosis</brief_title>
	<detailed_description>This study evaluate safety tolerability IFN-g 1b patient advance liver fibrosis cirrhosis due hepatitis C. This study also evaluate whether IFN-g 1b effective reduce amount fibrosis liver .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Men woman 18 75 year Chronic hepatitis C infection base history positive antiHCV antibody and/or HCV RNA History prior treatment interferonabased therapy assessment investigator patient would benefit interferonabased therapy treatment interferona contraindicate Stage 4 , 5 6 liver fibrosis accord Ishak scoring system . Can presence clinically evident ascites require active diuretic therapy , history therapy hepatic encephalopathy , history GI variceal bleed within last 2 year ( diuretic therapy stable mildtomoderate peripheral edema permit ) Must meet minimum blood chemistry requirement Can unstable uncontrolled thyroid disease Can variety disease ( list protocol Other condition enrollment exist would discuss Clinician upon screen study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>liver fibrosis</keyword>
	<keyword>liver cirrhosis</keyword>
</DOC>